Neoplasm malignant+1
RecruitingStudy of ECI830, ribociclib, and fulvestrant in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors
Study of ECI830, ribociclib, and fulvestrant in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors
- Disease:Neoplasm malignantHormone receptor positive HER2 negative breast cancer
- Substances:ECI830Fulvestrant+3
Spain- Participants:18–64 years · 65+ years
- Substances:ECI830
- Sponsor:Novartis Pharma AG










